Follow-up of six patients with neurofibromatosis 1-related osteoporosis treated with alendronate for 23 months

Calcified Tissue International

Volumn 94, Issue 6, 2014, Pages 608-612

  Heervä, Eetu ^a   Huilaja, Laura ^b   Leinonen, Pekka ^b,c   Peltonen, Sirkku ^d   Peltonen, Juha ^a  

^a UNIVERSITY OF TURKU   (Finland)

^b OULU UNIVERSITY HOSPITAL   (Finland)

^c KAINUU CENTRAL HOSPITAL   (Finland)

^d TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

BMD; Bone dynamics; Osteoclast; Ras; von Recklinghausen

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CARBOXY TERMINAL TELOPEPTIDE; PROCOLLAGEN; PROCOLLAGEN TYPE I AMINO TERMINAL PROPEPTIDE; TARTRATE RESISTANT ACID PHOSPHATASE 5B; UNCLASSIFIED DRUG; VITAMIN D; BONE DENSITY CONSERVATION AGENT;

ADULT; AGED; APOPTOSIS; ARTICLE; BLOOD LEVEL; BONE DENSITY; BONE REMODELING; BONE TURNOVER; CLINICAL ARTICLE; DRUG EFFICACY; FEMALE; FOLLOW UP; FRACTURE; HUMAN; IN VITRO STUDY; MALE; NEUROFIBROMATOSIS; OSTEOCLAST; OSTEOPENIA; OSTEOPOROSIS; PRIORITY JOURNAL; RISK REDUCTION; SIGNAL TRANSDUCTION; STRESS FRACTURE; TIBIA FRACTURE; VERY ELDERLY; VITAMIN SUPPLEMENTATION; CLINICAL TRIAL; COMPLICATION; DRUG EFFECTS; MIDDLE AGED;

ADULT; AGED; ALENDRONATE; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE REMODELING; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEUROFIBROMATOSIS 1; OSTEOPOROSIS;

EID: 84901984865     PISSN: 0171967X     EISSN: 14320827     Source Type: Journal    
DOI: 10.1007/s00223-013-9835-2     Document Type: Article

References (28)

1. Riccardi V, Eichner J (1986) Neurofibromatosis: phenotype, natural history and pathogenesis. Johns Hopkins University Press, Baltimore
2. Huson S (2008) The neurofibromatoses: classification, clinical features and genetic counseling. In: Kaufmann D (ed) Neurofibromatoses. Monographs in human genetics, Karger, pp 1-20
3. Jouhilahti EM, Peltonen S, Heape A, Peltonen J (2011) Pathoetiology of neurofibromatosis. Am J Pathol 178:1932-1939
4. Xu G, O'Connell P, Viskochil D, Cawthon R, Robertson M, Culver M, Dunn D, Stevens J, Gesteland R, White R (1990) The neurofibromatosis type 1 gene encodes a protein related to GAP. Cell 62:599-608
5. Stumpf D, Annergers J, Brown S, Conneally P, Housman D, Leppert M, Miller J, Moss M, Pileggi A, Rapin I, Strohman R, Swanson L, Zimmersman A (1988) Neurofibromatosis. Conference statement. National Institutes of Health Consensus Development Conference. Arch Neurol 45:575-578
6. Peltonen S, Poyhonen M (2012) Clinical diagnosis and atypical forms of NF1. In: Upadhyaya M, Cooper D (eds) Neurofibromatosis type 1: molecular and cellular biology. Springer, Berlin, pp 17-30
7. Elefteriou F, Kolanczyk M, Schindeler A et al (2009) Skeletal abnormalities in neurofibromatosis type 1: approaches to therapeutic options. Am J Med Genet A 149:2327-2338
8. Kuorilehto T, Pöyhönen M, Bloigu R, Heikkinen J, Väänänen K, Peltonen J (2005) Decreased bone mineral density and content in neurofibromatosis type 1: lowest local values are located in the load-carrying parts of the body. Osteoporos Int 16:928-936 (Pubitemid 41127102)
9. Brunetti-Pierri N, Doty S, Hicks J, Phan K, Mendoza-Londono R, Blazo M, Tran A, Carter S, Lewis R, Plon S, Phillips W, O'Brian Smith E, Ellis K, Lee B (2008) Generalized metabolic bone disease in neurofibromatosis type I. Mol Genet Metab 94:105-111
10. Tucker T, Schnabel C, Hartmann M, Friedrich R, Frieling I, Kruse H, Mautner V, Friedman J (2009) Bone health and fracture rate in individuals with neurofibromatosis 1 (NF1). J Med Genet 46:259-265
11. Petramala L, Giustini S, Zinnamosca L, Marinelli C, Colangelo L, Cilenti G, Formicuccia M, D'Erasmo E, Calvieri S, Letizia C (2012) Bone mineral metabolism in patients with neurofibromatosis type 1 (von Recklinghausen disease). Arch Dermatol Res 304:325-331
12. Heervä E, Peltonen S, Svedström E, Aro HT, Väänä nen K, Peltonen J (2012) Osteoclasts derived from patients with neurofibromatosis 1 (NF1) display insensitivity to bisphosphonates in vitro. Bone 50:798-803
13. Heervä E, Leinonen P, Kuorilehto T, Peltonen S, Pöyhönen M, Väänänen K, Peltonen J (2013) Neurofibromatosis 1-related osteopenia often progresses to osteoporosis in 12 years. Calcif Tissue Int 92:23-27
14. Heervä E, Koffert A, Jokinen E, Kuorilehto T, Peltonen S, Aro HT, Peltonen J (2012) A controlled register-based study of 460 neurofibromatosis 1 patients: increased fracture risk in children and adults over 41 years of age. J Bone Miner Res 27:2333-2337
15. George-Abraham J, Martin L, Kalkwarf H, Rieley M, Stevenson D, Viskochil D, Hopkin R, Stevens A, Hanson H, Schorry E (2013) Fractures in children with neurofibromatosis type 1 from two NF clinics. Am J Med Gen A 161:921-926
16. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy (2001) Osteoporosis prevention, diagnosis, and therapy. JAMA 285:785-795
17. Lewiecki E, Gordon C, Baim S, Binkley N, Bilezikian J, Kendler D, Hans D, Silverman S, Bishop N, Leonard M, Bianchi M, Kalkwarf H, Langman C, Plotkin H, Rauch F, Zemel B (2008) Special report on the 2007 adult and pediatric Position Development Conferences of the International Society for Clinical Densitometry. Osteoporos Int 19:1078-1369
18. Bergstrom J, Bostedor R, Masarachia P, Reszka A, Rodan G (2000) Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase. Arch Biochem Biophys 373:231-234
19. Dunford J, Rogers M, Ebetino F, Phipps R, Coxon F (2006) Inhibition of protein prenylation by bisphosphonates causes sustained activation of Rac, Cdc42, and Rho GTPases. J Bone Miner Res 21:684-694
20. Gallacher S, Dixon T (2010) Impact of treatments for postmenopausal osteoporosis (bisphosphonates, parathyroid hormone, strontium ranelate, and denosumab) on bone quality: a systematic review. Calcif Tissue Int 87:469-484
21. Reginster J (2011) Antifracture efficacy of currently available therapies for postmenopausal osteoporosis. Drugs 71:65-78
22. Vasikaran S, Eastell R, Bruyère O, Foldes A, Garnero P, Griesmacher A, McClung M, Morris H, Silverman S, Trenti T, Wahl D, Cooper C, Kanis J (2011) Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int 22:391-420
23. Cummings S, Black D, Thompson D, Applegate W, Barrett-Connor E, Musliner T, Palermo L, Prineas R, Rubin S, Scott J, Vogt T, Wallace R, Yates A, LaCroix A (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 280:2077-2082 (Pubitemid 29014065)
24. Tonino R, Meunier P, Emkey R, Rodriguez-Portales J, Menkes C, Wasnich R, Bone H, Santora A, Wu M, Desai R, Ross P (2000) Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study Group. J Clin Endocrinol Metab 85:3109-3115
25. Bone H, Hosking D, Devogelaer J, Tucci J, Emkey R, Tonino R, Rodriguez-Portales J, Downs R, Gupta J, Santora A, Liberman U (2004) Alendronate Phase III Osteoporosis Treatment Study Group. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350:1189-1199 (Pubitemid 38339363)
26. Rosen C, Hochberg M, Bonnick S, McClung M, Miller P, Broy S, Kagan R, Chen E, Petruschke R, Thompson D, de Papp A (2005) Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study. J Bone Miner Res 20:141-151 (Pubitemid 41716229)
27. Nenonen A, Cheng S, Ivaska K, Alatalo S, Lehtimäki T, Schmidt-Gayk H, Uusi-Rasi K, Heinonen A, Kannus P, Sievänen H, Vuori I, Väänänen K, Halleen J (2005) Serum TRAP 5b is a useful marker for monitoring alendronate treatment: comparison with other markers of bone turnover. J Bone Miner Res 20:1804-1812 (Pubitemid 41361881)
28. Birke O, Schindeler A, Ramachandran M, Cowell C, Munns C, Bellemore M, Little D (2010) Preliminary experience with the combined use of recombinant bone morphogenetic protein and bisphosphonates in the treatment of congenital pseudarthrosis of the tibia. J Child Orthop 4:507-517